AR and prostate carcinoma: However, this proposed mechanism of action by AR activation cannot explain the expression of T:E fusion gene in advanced metastatic hormone therapy-resistant prostate cancer and AR-negative and androgen-independent prostate cancer cells [12, 16, 17, 21].